Question 1

Does Balyasny Asset Management own MLTX stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Balyasny Asset Management holds 912,715 shares of MLTX (Moonlake Immunotherapeutics), worth $17.8M.

Question 2

How many shares of MLTX does Balyasny Asset Management own?

Accepted Answer

As of its Q2 2026 13F, Balyasny Asset Management holds 912,715 shares of MLTX (Moonlake Immunotherapeutics).

Question 3

What is Balyasny Asset Management's MLTX position worth?

Accepted Answer

As of its Q2 2026 13F, Balyasny Asset Management's MLTX position is worth $17.8M.

Question 4

Is Balyasny Asset Management buying or selling MLTX?

Accepted Answer

In Q2 2026, Balyasny Asset Management reduced its MLTX position by 152,895 shares (-14.4%).

Question 5

When did Balyasny Asset Management first buy MLTX?

Accepted Answer

Balyasny Asset Management first reported MLTX in its Q3 2022 13F and has listed it in 16 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	912,715	-14.3%	$17.8M	0.0%	$19.47	0
2026-Q1	Decreased	1.1M	-32.2%	$19.9M	0.0%	$17.69	0
2025-Q4	Decreased	1.6M	-7.5%	$20.7M	0.0%	$13.21	0
2025-Q3	Increased	1.7M	+301.6%	$12.2M	0.0%	$6.24	45
2025-Q2	Increased	423,170	+436.8%	$20M	0.0%	$47.52	46
2025-Q1	Decreased	78,835	-61.8%	$3.1M	0.0%	$39.86	0
2024-Q4	Decreased	206,568	-42.6%	$11.2M	0.0%	$53.02	0
2024-Q3	Decreased	360,200	-38.4%	$18.2M	0.0%	$49.40	0